Bosutinib (BOS) versus imatinib for newly diagnosed chronic phase (CP) chronic myeloid leukemia (CML): Final 5-year results from the BFORE trial Meeting Abstract
| Authors: | Brümmendorf, T. H.; Cortes, J. E.; Milojkovic, D.; Gambacorti-Passerini, C.; Clark, R. E.; le Coutre, P. D.; Garcia-Gutiérrez, V.; Chuah, C.; Kota, V.; Lipton, J. H.; Rousselot, P.; Mauro, M. J.; Hochhaus, A.; Monroy, R. H.; Leip, E.; Purcell, S.; Yver, A.; Viqueira, A.; Deininger, M. W. |
| Abstract Title: | Bosutinib (BOS) versus imatinib for newly diagnosed chronic phase (CP) chronic myeloid leukemia (CML): Final 5-year results from the BFORE trial |
| Meeting Title: | 62nd Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 136 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2020 Dec 5-8 |
| Meeting Location: | Virtual |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2020-11-05 |
| Language: | English |
| ACCESSION: | WOS:000607547200128 |
| DOI: | 10.1182/blood-2020-137393 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 41 -- Source: Wos |
